470 related articles for article (PubMed ID: 35707003)
1. Comprehensive Analysis Identifies PI3K/Akt Pathway Alternations as an Immune-Related Prognostic Biomarker in Colon Adenocarcinoma Patients Receiving Immune Checkpoint Inhibitor Treatment.
Lin A; Gu T; Hu X; Zhang J; Luo P
J Immunol Res; 2022; 2022():8179799. PubMed ID: 35707003
[TBL] [Abstract][Full Text] [Related]
2. Analysis of Interleukin-1 Signaling Alterations of Colon Adenocarcinoma Identified Implications for Immunotherapy.
Zhou X; Liu Y; Xiang J; Wang Y; Wang Q; Xia J; Chen Y; Bai Y
Front Immunol; 2021; 12():665002. PubMed ID: 34367132
[TBL] [Abstract][Full Text] [Related]
3. Mutations Status of Chemokine Signaling Pathway Predict Prognosis of Immune Checkpoint Inhibitors in Colon Adenocarcinoma.
Lin A; Xu W; Luo P; Zhang J
Front Pharmacol; 2021; 12():721181. PubMed ID: 34721019
[TBL] [Abstract][Full Text] [Related]
4. Exploration of the relationship between tumor mutation burden and immune infiltrates in colon adenocarcinoma.
Ouyang R; Li Z; Peng P; Zhang J; Liu J; Qin M; Huang J
Int J Med Sci; 2021; 18(3):685-694. PubMed ID: 33437203
[No Abstract] [Full Text] [Related]
5. High expression of PI4K2A predicted poor prognosis of colon adenocarcinoma (COAD) and correlated with immunity.
Huang X; Cao Y; Bao P; Zhu B; Cheng Z
Cancer Med; 2023 Jan; 12(1):837-851. PubMed ID: 35634680
[TBL] [Abstract][Full Text] [Related]
6. TNF-Alpha Pathway Alternation Predicts Survival of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.
Lin A; Zhang H; Meng H; Deng Z; Gu T; Luo P; Zhang J
Front Immunol; 2021; 12():667875. PubMed ID: 34603277
[TBL] [Abstract][Full Text] [Related]
7. Effect of TTN Mutations on Immune Microenvironment and Efficacy of Immunotherapy in Lung Adenocarcinoma Patients.
Wang Z; Wang C; Lin S; Yu X
Front Oncol; 2021; 11():725292. PubMed ID: 34513703
[TBL] [Abstract][Full Text] [Related]
8. Construction of a novel choline metabolism-related signature to predict prognosis, immune landscape, and chemotherapy response in colon adenocarcinoma.
Liu C; Liu D; Wang F; Liu Y; Xie J; Xie J; Xie Y
Front Immunol; 2022; 13():1038927. PubMed ID: 36451813
[TBL] [Abstract][Full Text] [Related]
9. Predictive Models for Colon Adenocarcinoma Diagnosis, Prognosis, and Immune Microenvironment Based on 2 Hypoxia-Related Genes: KDM3A and ENO3.
Kong C; Zheng L; Fang S; Chen M; Lin G; Qiu R; Zhao Z; Chen W; Song J; Yang Y; Ji J
Technol Cancer Res Treat; 2023; 22():15330338231195494. PubMed ID: 37650153
[No Abstract] [Full Text] [Related]
10. TET1 mutations as a predictive biomarker for immune checkpoint inhibitors in colon adenocarcinoma.
Qiu T; Wang X; Du F; Hu X; Sun F; Song C; Zhao J
World J Surg Oncol; 2022 Apr; 20(1):115. PubMed ID: 35395805
[TBL] [Abstract][Full Text] [Related]
11. The mutational pattern of homologous recombination-related (HRR) genes in Chinese colon cancer and its relevance to immunotherapy responses.
Zhou P; Wu X; Chen H; Hu Y; Zhang H; Wu L; Yang Y; Mao B; Wang H
Aging (Albany NY); 2020 Dec; 13(2):2365-2378. PubMed ID: 33318301
[TBL] [Abstract][Full Text] [Related]
12. The Predictive Value of PAK7 Mutation for Immune Checkpoint Inhibitors Therapy in Non-Small Cell Cancer.
Zeng H; Tong F; Bin Y; Peng L; Gao X; Xia X; Yi X; Dong X
Front Immunol; 2022; 13():834142. PubMed ID: 35242138
[TBL] [Abstract][Full Text] [Related]
13. An Intratumor Heterogeneity-Related Signature for Predicting Prognosis, Immune Landscape, and Chemotherapy Response in Colon Adenocarcinoma.
Liu C; Liu D; Wang F; Xie J; Liu Y; Wang H; Rong J; Xie J; Wang J; Zeng R; Zhou F; Xie Y
Front Med (Lausanne); 2022; 9():925661. PubMed ID: 35872794
[TBL] [Abstract][Full Text] [Related]
14. Identification of the six-hormone secretion-related gene signature as a prognostic biomarker for colon adenocarcinoma.
Jia X; Zhang T; Lv X; Du H; Sun Y; Guan Y
Cancer Biomark; 2023; 38(4):523-535. PubMed ID: 38143338
[TBL] [Abstract][Full Text] [Related]
15. A novel signature model based on mitochondrial-related genes for predicting survival of colon adenocarcinoma.
Gao H; Xing F
BMC Med Inform Decis Mak; 2022 Oct; 22(1):277. PubMed ID: 36273131
[TBL] [Abstract][Full Text] [Related]
16. Identification prognosis-associated immune genes in colon adenocarcinoma.
Miao Y; Wang J; Ma X; Yang Y; Mi D
Biosci Rep; 2020 Nov; 40(11):. PubMed ID: 33140821
[TBL] [Abstract][Full Text] [Related]
17. Fibroblast growth factor receptor family mutations as a predictive biomarker for immune checkpoint inhibitors and its correlation with tumor immune microenvironment in melanoma.
Zhang W; Xia H; Yang R; Zhang Y; Zheng Q; Shang X; Liu N; Ma X; Wei C; Chen H; Mu X; Wang X; Liu Y
Front Immunol; 2022; 13():1030969. PubMed ID: 36426352
[TBL] [Abstract][Full Text] [Related]
18. Prognosis of Lung Adenocarcinoma Patients With NTRK3 Mutations to Immune Checkpoint Inhibitors.
Niu Y; Lin A; Luo P; Zhu W; Wei T; Tang R; Guo L; Zhang J
Front Pharmacol; 2020; 11():1213. PubMed ID: 32903385
[TBL] [Abstract][Full Text] [Related]
19.
Sun Y; Li L; Yao W; Liu X; Yang Y; Ma B; Xue D
Front Genet; 2021; 12():762160. PubMed ID: 34795697
[TBL] [Abstract][Full Text] [Related]
20. Crosstalk Between the MSI Status and Tumor Microenvironment in Colorectal Cancer.
Lin A; Zhang J; Luo P
Front Immunol; 2020; 11():2039. PubMed ID: 32903444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
